Dr. Reddy’s Laboratories is a global pharmaceutical company that began in 1984 making active pharmaceutical ingredients (APIs - the chemical building blocks of drugs) and has spent four decades evolving into a diversified enterprise that now spans generics, branded medicines, biosimilars, consumer health, and drug discovery. Its defining approach is a two-horizon strategy: it runs a large core business of generics and APIs to generate near-term growth, while simultaneously scaling newer ventures like biosimilars, consumer healthcare, and novel therapies for the long term. The company’s stated purpose - “Good Health Can’t Wait” - translates into a recurring pattern of making expensive or complex medicines accessible, whether by launching the first generic version of a drug, building a portfolio of trusted brands in emerging markets, or in-licensing innovative therapies for patients in India and beyond. # Business segments Three engines at different stages - a global generics powerhouse spanning four continents, a pharmaceutical services and ingredients backbone, and a consumer healthcare platform built on a recent marquee acquisition - each feeding the next phase of the company’s expansion. ## 1. Global Generics: where the company’s scale and reach sit **A generics business that sells branded and unbranded prescription medicines, over-the-counter products, and biosimilars across North America, Europe, India, and emerging markets - contributing roughly 89% of overall revenue - with a model built on volume, first-to-market launches, and a portfolio of over 335 products.** - **America is the anchor** - the North America generics business alone accounts for about half of Global Generics sales, where the company is ranked 8th in the US generics market and sells to wholesalers, distributors, and pharmacy chains on a per-unit basis. It offsets the steady price erosion that comes with generics by continuously launching new products, including complex injectables and first-to-market opportunities like the recent Bosutinib launch with 180 days of exclusivity. - **Europe is the biosimilar and branded beachhead** - the European business, which has doubled in size, now serves 36 markets and is where the company launched its first biosimilar (bevacizumab) with its own commercial team in the UK. It is also the home of the newly acquired Nicotinell NRT brand, a 30-year-old OTC franchise that holds a 22-23% share of the ex-US nicotine replacement category. - **Bought as well as built** - the generics engine has been shaped by targeted acquisitions: a portfolio of 45 commercial products from Mayne Pharma in the US, injectable brands from Eton Pharmaceuticals, the Stugeron anti-vertigo brand across 18 markets, and hormone replacement therapy brands in India. ## 2. Pharmaceutical Services and Active Ingredients: the chemical engine underneath **A combined API manufacturing and contract development business that supplies the starting materials for its own generics and for other drug companies, while also making novel drugs for innovator clients - contributing 10% of revenue and providing cost and supply-chain leverage.** - **Backward integration is the moat** - the company makes its own APIs for many of its finished drugs, with an aim to backward-integrate more than 70% of its core molecules, which gives it control over costs and supply assurance that pure-play formulators lack. It has filed over 1,700 global drug master files and freed half a million effort hours through process simplification. - **Institutional reach with a public-health angle** - the API business also sells value-added products to institutions in over 25 countries, and its Health Access Business aims to impact 500 million lives by working with public health bodies, building on the 5 million lives reached during Covid-19. ## 3. Consumer Healthcare: the new front door to the patient **A consumer health business anchored by the Nicotinell nicotine replacement franchise acquired from Haleon - the world’s second-largest NRT brand - and extended through OTC acquisitions in the US and a nutraceuticals joint venture with Nestlé in India.** - **The NRT acquisition is the cornerstone** - bought for a total consideration of GBP 500 million and 95% integrated by March 2026, the Haleon portfolio brings a brand with a 30-year heritage, presence on the WHO Essential Medicines List, and a 22-23% share of the global ex-US NRT market across all formats (patches, gum, lozenges). The company plans to invest in advertising, launch new formats, and expand the brand into geographies where it already has a commercial footprint. - **US OTC brands fill out the shelf** - the company has acquired a string of American over-the-counter brands including Habitrol (NRT), Doan’s (pain relief), and the Premama and MenoLabs portfolios in women’s health and menopause supplements. - **A joint venture for nutrition in India** - a 51:49 partnership with Nestlé India combines Nestlé’s global supplement brands like Nature’s Bounty with Dr. Reddy’s own Celevida and Rebalanz ranges, targeting metabolic health, hospital nutrition, and general wellness, with an ambition to eventually manufacture complex products locally. # Group structure and partners **A parent company in Hyderabad with a web of subsidiaries and joint ventures that execute the global strategy - from a Swiss holding entity for the NRT acquisition to a US generics arm, a dedicated oncology R&D unit, and a nutraceuticals JV with Nestlé.** - Aurigene Pharmaceutical Services Limited runs the CDMO business, and Aurigene Oncology Limited is the wholly-owned clinical-stage biotech focused on novel cancer and inflammation therapies, with a proprietary protein-degradation platform and three assets in clinical trials. - The 51:49 joint venture with Nestlé India, operational since August 2024, gives Nestlé a call option to increase its stake to 60% after six years, while Dr. Reddy’s retains at least 40%.